Tag:

Boehringer Ingelheim

Latest Headlines

Latest Headlines

EU panel backs slew of new drugs and uses, boosting Lilly, AZ, Novartis, Gilead and more

When Europe's drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.

FDA's Mini-Sentinel set to graduate on October 1

The FDA's Mini-Sentinel has long since outgrown its "mini" moniker and is now ready to graduate from being a pilot project to being an integral part of the agency's drug-safety infrastructure. Many people welcome the program's progress, but doubts and dissenting voices remain.

Faltering Boehringer slashes 600 jobs in Germany in bid to save $580M

The bloodletting in Big Pharma continues with news today that Boehringer Ingelheim is planning between 500 and 600 job cuts in its home country of Germany. The cuts come just a few weeks after the company announced its sales had dropped 3% in the first 6 months of the year and full-year results would likely be down slightly from last year.

Boehringer pairs its lung cancer drug with a vaccine in $600M tie-up with CureVac

A little more than two months after inking a licensing deal with Sanofi, CureVac has completed another tie-up, banking a $45 million upfront from Boehringer Ingelheim and partnering its therapeutic vaccine aimed at lung cancer. The deal also includes up to about $556 million in prospective milestones for the German biotech.

Lilly and Boehringer snag EU nod for Lantus knockoff, but stateside hopes stay on ice

Eli Lilly and Boehringer Ingelheim won European clearance for their biosimilar of Lantus, Sanofi's top-selling insulin product, but the treatment's full potential remains hamstrung by a U.S. patent challenge.

Boehringer's next-gen COPD treatment hits the mark in Phase III

Boehringer Ingelheim met its main goals in a late-stage study on a new COPD treatment, clearing the way for regulatory approvals and a bout with rival GlaxoSmithKline.

UPDATED: Will little-known company's inhaled candidate take down InterMune-Roche's pirfenidone?

Roche's announcement that it will acquire InterMune and its orally delivered drug pirfenidone has pushed the rare lung condition idiopathic pulmonary fibrosis (IPF) into the spotlight. Boehringer Ingelheim also has an oral drug for IPF on the horizon, but a little-known candidate for the condition has the potential to steal the big boys' thunder due to its differentiated delivery mechanism. 

Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program

Boehringer Ingelheim said it will end research into developing a porcine circovirus type 2 ready-to-use vaccine combination to focus its attention on its PCV2 Mycoplasma hyopneumoniae vaccine.

Boehringer Ingelheim recalls cancer drug made at ill-fated Bedford plant

Boehringer Ingelheim is still recalling products that were made at its Ben Venue plant in Bedford, OH, even though it no longer owns the massive site.

Boehringer Ingelheim still being dogged by Ben Venue plant

Boehringer Ingelheim is finding it difficult to get the stink of the troubled Ben Venue Bedford, OH, operations off its shoes. It closed the site last year and sold it last month but is still having to recall products produced there that might be contaminated.